Clinical Data from Phase 2 SPRING Trial Shows CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of PSC

At the AASLD The Liver Meeting® 2024, PSC expert Dr. Chris Bowlus presented data from the CM-101 Phase 2 SPRING trial in patients with PSC. 

Dr. Bowlus described how CM-101 was well tolerated and that it demonstrated dose-dependent anti-inflammatory, anti-fibrotic and anti-cholestatic effects. PSC patients with moderate advanced disease treated with CM-101 showed broad and consistent improvement in biomarkers associated with clinical outcomes. He concluded these findings support further clinical development of CM-101 in patients with PSC. 

Image credit Chemomab

Chemomab CMO Matt Frankel, MD, noted, “CM-101 is the first investigative therapy for PSC to demonstrate such broad activity across a range of biomarkers representing all major components of the disease…and we look forward to meeting with the FDA before the end of the year to agree on a path forward to a PSC registrational trial."